| Wed 13 Jul 2022, 15:00 | | MEDICLINIC INTERNATIONAL PLC - TR-1: Standard form for notification of major holdings |
|
TR-1: Standard form for notification of major holdings
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(‘Mediclinic’, or the ‘Company’, or the ‘Group’)
13 July 2022
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00B8HX8Z88
Issuer Name
MEDICLINIC INTERNATIONAL PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of financial instruments
3. Details of person subject to the notification obligation
Name
JPMorgan Chase & Co.
City of registered office (if applicable)
Country of registered office (if applicable)
US
4. Details of the shareholder
Name City of registered office Country of registered office
J.P. Morgan Securities plc
5. Date on which the threshold was crossed or reached
08-Jul-2022
6. Date on which Issuer notified
12-Jul-2022
7. Total positions of person(s) subject to the notification
obligation
% of voting
% of voting rights through
Total of both Total number of
rights attached financial
. in % (8.A + voting rights
to shares (total instruments
8.B) held in issuer
of 8.A) (total of 8.B 1 +
8.B 2)
Resulting
situation on the
date on which
0.778294 4.386183 5.164477 38075042
threshold was
crossed or
reached
Position of
previous
n/a n/a n/a
notification (if
applicable)
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of Number of Number of indirect % of direct
% of indirect voting
shares ISIN direct voting voting rights voting rights
rights (DTR5.2.1)
code(if possible) rights (DTR5.1) (DTR5.2.1) (DTR5.1)
GB00B8HX8Z88 5737935 0.778294
Sub Total 8.A 5737935 0.778294%
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Number of voting rights that
% of
Type of financial Expiration Exercise/conversion may be acquired if the
voting
instrument date period instrument is
rights
exercised/converted
Sub Total 8.B1
8B2. Financial Instruments with similar economic effect
according to (DTR5.3.1R.(1) (b))
Type of Physical or
Exercise/conversion Number of % of voting
financial Expiration date cash
period voting rights rights
instrument settlement
Cash-
settled
23/11/2022 23/11/2022 Cash 17299211 2.346467
Equity
Swap
Cash-
settled
04/01/2023 04/01/2023 Cash 137352 0.018629
Equity
Swap
Cash-
settled
01/02/2023 01/02/2023 Cash 16152 0.002190
Equity
Swap
Cash-
settled
22/02/2023 22/02/2023 Cash 40742 0.005524
Equity
Swap
Cash-
settled
17/03/2023 17/03/2023 Cash 32829 0.004452
Equity
Swap
Cash-
settled
30/05/2023 30/05/2023 Cash 27875 0.003780
Equity
Swap
Cash-
settled
02/06/2023 02/06/2023 Cash 8031342 1.089370
Equity
Swap
Cash-
settled
04/07/2023 04/07/2023 Cash 5541353 0.751627
Equity
Swap
Cash-
settled
12/07/2023 12/07/2023 Cash 12409 0.001681
Equity
Swap
Cash-
settled
09/08/2023 09/08/2023 Cash 759 0.000102
Equity
Swap
Cash-
settled
04/09/2023 04/09/2023 Cash 17463 0.002367
Equity
Swap
Cash-
settled
11/01/2024 11/01/2024 Cash 58004 0.007866
Equity
Swap
Cash-
settled
05/01/2027 05/01/2027 Cash 891148 0.120872
Equity
Swap
Cash-
settled
02/07/2027 02/07/2027 Cash 164751 0.022344
Equity
Swap
Cash-
settled
06/07/2027 06/07/2027 Cash 436 0.000059
Equity
Swap
Cash-
settled
09/07/2029 09/07/2029 Cash 65281 0.008853
Equity
Swap
Sub Total 8.B2 32337107 4.386183%
9. Information in relation to the person subject to the
notification obligation
2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add
additional rows as necessary)
% of voting % of voting rights
rights if it through financial Total of both if it
Ultimate Name of controlled equals or is instruments if it equals or is higher
controlling person undertaking higher than equals or is higher than the notifiable
the notifiable than the notifiable threshold
threshold threshold
JPMorgan J.P. Morgan
4.386183 4.386183%
Chase & Co. Securities plc
JPMorgan
JPMorgan Chase Bank,
Chase & Co. National
Association
J.P. Morgan
Equities
JPMorgan
South Africa
Chase & Co.
Proprietary
Limited
JPMorgan J.P. Morgan
Chase & Co. SE
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Chain of controlled undertakings:
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Securities plc (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Equities South Africa Proprietary Limited (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan SE (100%)
12. Date of Completion
12-Jul-2022
13. Place Of Completion
London
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa
in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle
East.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and trusted
provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare
in each of its markets.
At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 20 day case clinics and 20 outpatient clinics. The Swiss operations included 17 hospitals
and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50
hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day
case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient
beds; and the Middle East operated seven hospitals, two day case clinics and 20 outpatient clinics
with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle East
will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.
The Company's primary listing is on the London Stock Exchange ('LSE') in the UK, with secondary
listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare
group based in the UK and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, UK
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 13-07-2022 03:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
